Description

SAR441255 TFA is a synthetic unimolecular peptide designed as a GLP-1/GIP/GCG receptor triagonist. It provides balanced activation of all three target receptors, offering robust metabolic regulation in preclinical models, including diabetic obese monkeys. SAR441255 TFA exhibits potent acute glucoregulatory effects, making it a valuable tool for studies on glucose homeostasis, energy balance, and metabolic disorders. Manufactured under GMP conditions with purity ??99.93%, it ensures consistency and reliability for experimental research in endocrinology and pharmacology.

Product Specifications

Mechanism of Action & Research Applications

SAR441255 TFA is a potent triagonist targeting GLP-1, GIP, and GCG receptors. Its main mechanisms and applications in research include:

• Balanced Receptor Activation: Simultaneously engages GLP-1, GIP, and GCG receptors for coordinated metabolic effects.

• Glucoregulatory Effects: Promotes acute glucose control in preclinical diabetic models.

• Energy Homeostasis: Influences appetite, insulin secretion, and energy expenditure pathways.

• Metabolic Research: Useful for experimental studies in obesity, diabetes, and related metabolic disorders.

• Neuroendocrine Impact: Modulates gut-pancreas-brain axis signaling for holistic metabolic regulation.

This triagonist peptide serves as a versatile tool for endocrinology and pharmacological research, providing insights into therapeutic strategies for metabolic diseases.

Side Effects (For Reference Only in Models)

In preclinical models, SAR441255 TFA is generally well tolerated. Reported effects include transient changes in glucose levels or minor gastrointestinal responses. No clinical or human-use data is included; research is limited to laboratory studies.

Disclaimer

SAR441255 TFA is intended strictly for laboratory research use only. It is not approved for clinical or therapeutic applications. Follow institutional safety protocols during handling.